{'52WeekChange': 0.6241379,
 'SandP52WeekChange': None,
 'address1': '33 Hayden Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 23.17,
 'askSize': 1800,
 'averageDailyVolume10Day': 544912,
 'averageVolume': 680122,
 'averageVolume10days': 544912,
 'beta': 1.807843,
 'beta3Year': None,
 'bid': 23.1,
 'bidSize': 1000,
 'bookValue': 2.411,
 'category': None,
 'circulatingSupply': None,
 'city': 'Lexington',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 23.51,
 'dayLow': 22.57,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -8.315,
 'enterpriseToRevenue': 18.75,
 'enterpriseValue': 1027956736,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 612 6298',
 'fiftyDayAverage': 23.624144,
 'fiftyTwoWeekHigh': 27.68,
 'fiftyTwoWeekLow': 11.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 57016157,
 'forwardEps': -0.52,
 'forwardPE': -44.51923,
 'fromCurrency': None,
 'fullTimeEmployees': 187,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.07491,
 'heldPercentInstitutions': 0.83074,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/dicerna.com',
 'longBusinessSummary': 'Dicerna Pharmaceuticals, Inc., a biopharmaceutical '
                        'company, focuses on the discovery and development of '
                        'ribonucleic acid interference (RNAi)-based '
                        'pharmaceuticals. The company develops pharmaceuticals '
                        'using its GalXC RNAi platform for the treatment of '
                        'diseases involving the liver, including rare '
                        'diseases, viral infectious diseases, chronic liver '
                        'diseases, and cardiometabolic diseases. Its principal '
                        'development programs include nedosiran for the '
                        'treatment of primary hyperoxaluria; RG6346 for the '
                        'treatment of chronic hepatitis B virus infection; and '
                        'a program for an undisclosed rare liver disease. The '
                        "company's development programs also comprise DCR-A1AT "
                        'programs; and a program for the treatment of '
                        'neurodegeneration and pain. Dicerna Pharmaceuticals, '
                        'Inc. has strategic collaborations with Novo Nordisk '
                        'A/S, Roche, Eli Lilly and Company, Alnylam '
                        'Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., '
                        'and Boehringer Ingelheim International GmbH. The '
                        'company was founded in 2006 and is headquartered in '
                        'Lexington, Massachusetts.',
 'longName': 'Dicerna Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1711164672,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_39280611',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -116797000,
 'nextFiscalYearEnd': 1640908800,
 'open': 23.2,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 621 8097',
 'previousClose': 23.55,
 'priceHint': 2,
 'priceToBook': 9.601825,
 'priceToSalesTrailing12Months': 31.211393,
 'profitMargins': -2.13036,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 23.51,
 'regularMarketDayLow': 22.57,
 'regularMarketOpen': 23.2,
 'regularMarketPreviousClose': 23.55,
 'regularMarketPrice': 23.2,
 'regularMarketVolume': 408606,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 73916400,
 'sharesPercentSharesOut': 0.0584,
 'sharesShort': 4319220,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3206662,
 'shortName': 'Dicerna Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0619,
 'shortRatio': 5.17,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'DRNA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.678,
 'twoHundredDayAverage': 20.944317,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '90053ea4-02c4-330d-bf57-593c1505f61b',
 'volume': 408606,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.dicerna.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02421'}